Trials / Completed
CompletedNCT04900363
A Trial of AK112 (PD-1/VEGF Bispecific Antibody) in Patients With NSCLC
A Phase Ib/II Trial of AK112 (PD-1/VEGF Bispecific Antibody) in Patients With Advanced NSCLC
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 108 (actual)
- Sponsor
- Akeso · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This trial is a Phase Ib/II study. All patients are stage IIIB/C or IV non-small cell lung cancer(NSCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of AK112 in subjects with advanced NSCLC whose tumors have a programmed cell death-ligand 1 (PD-L1) Tumor Proportion Score (TPS) greater than or equal to 1%.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AK112 | Subjects receive AK112 intravenously. |
Timeline
- Start date
- 2021-05-21
- Primary completion
- 2024-06-28
- Completion
- 2025-12-09
- First posted
- 2021-05-25
- Last updated
- 2026-03-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04900363. Inclusion in this directory is not an endorsement.